CAPR insider trading
NasdaqCM HealthcareCAPRICOR THERAPEUTICS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About CAPRICOR THERAPEUTICS, INC.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; and CAP-2003, and allogeneic cardiosphere-derived cells-exosomes, which is in preclinical trial to treat DMD. It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Company website: www.capricor.com
CAPR insider activity at a glance
FilingIQ has scored 147 insider transactions for CAPR since Jan 21, 2015. The most recent filing in our index is dated May 13, 2026.
Across the full history, 49 open-market purchases
and 11 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CAPR insider trades is 57.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for CAPR?
- FilingIQ tracks 147 Form 4 insider transactions for CAPR (CAPRICOR THERAPEUTICS, INC.), covering filings from Jan 21, 2015 onwards. 27 of those were filed in the last 90 days.
- Are CAPR insiders net buyers or net sellers?
- Across the full Form 4 history for CAPR, 49 transactions (33%) were open-market purchases and 11 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CAPR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CAPR in?
- CAPRICOR THERAPEUTICS, INC. (CAPR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.59B.
Methodology & sources
Every CAPR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.